NZ606992A - Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids - Google Patents

Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids

Info

Publication number
NZ606992A
NZ606992A NZ606992A NZ60699211A NZ606992A NZ 606992 A NZ606992 A NZ 606992A NZ 606992 A NZ606992 A NZ 606992A NZ 60699211 A NZ60699211 A NZ 60699211A NZ 606992 A NZ606992 A NZ 606992A
Authority
NZ
New Zealand
Prior art keywords
hiv
prophylaxis
treatment
diseases caused
drug
Prior art date
Application number
NZ606992A
Other languages
English (en)
Inventor
Oleg Iliich Epshtein
Sergei Alexandrovich Tarasov
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45559675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ606992(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of NZ606992A publication Critical patent/NZ606992A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NZ606992A 2010-08-06 2011-07-15 Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids NZ606992A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010133045/15A RU2535033C2 (ru) 2010-08-06 2010-08-06 Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
PCT/RU2011/000523 WO2012018284A1 (ru) 2010-08-06 2011-07-15 Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида

Publications (1)

Publication Number Publication Date
NZ606992A true NZ606992A (en) 2016-03-31

Family

ID=45559675

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ606992A NZ606992A (en) 2010-08-06 2011-07-15 Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids

Country Status (14)

Country Link
US (1) US20130224219A1 (https=)
EP (1) EP2601967A4 (https=)
JP (1) JP2013538195A (https=)
CN (1) CN103209705A (https=)
AU (1) AU2011286486B9 (https=)
CA (1) CA2807540A1 (https=)
DE (1) DE112011102649T5 (https=)
EA (1) EA030411B1 (https=)
ES (1) ES2555557R1 (https=)
GB (1) GB2498276B (https=)
NZ (1) NZ606992A (https=)
RU (1) RU2535033C2 (https=)
UA (1) UA112747C2 (https=)
WO (1) WO2012018284A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
PH12013500107A1 (en) 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
EP2593474A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
EA029199B1 (ru) 2010-07-21 2018-02-28 Олег Ильич Эпштейн Комбинированная фармацевтическая композиция для лечения синдрома дефицита внимания и гиперактивности и способы лечения синдрома дефицита внимания и гиперактивности
WO2014116789A1 (en) * 2013-01-25 2014-07-31 Thymon, Llc Immunogenic and prophylactic compositions, methods of making same, and method for treating and preventing tnf-mediated disease and hiv-1 infection
JP6134392B2 (ja) 2013-01-25 2017-05-24 サイモン・エルエルシー 循環している生物学的に活性な可溶性ｔｎｆの選択的低減用の組成物およびｔｎｆ媒介性疾患を処置する方法
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4236069A1 (de) * 1992-10-26 1994-04-28 Werner Dr Bergmann Arzneimittel, insbesondere für orale Einnahme
NZ284214A (en) * 1994-03-31 1997-07-27 Biomed Comm Inc Extreme dilutions of growth factors, homeopathic compositions, radiotherapy.
US20030228310A1 (en) * 1996-12-23 2003-12-11 Advanced Biotherapy, Inc. Treatment of skin diseases
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
JP2000143537A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 細胞接着分子発現抑制剤
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2192888C1 (ru) * 2001-02-15 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома
RU2195317C1 (ru) * 2001-04-18 2002-12-27 Эпштейн Олег Ильич Способ коррекции патологических иммунных реакций и лекарственное средство
RU2001134982A (ru) * 2001-12-26 2004-02-20 Олег Ильич Эпштейн Способ коррекции иммунного ответа и лекарственное средство
RU2201255C1 (ru) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
RU2205025C1 (ru) * 2001-12-26 2003-05-27 Гольдберг Евгений Данилович Способ коррекции иммунного ответа и лекарственное средство
UA76640C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
RU2008110058A (ru) * 2005-08-15 2009-09-27 Арана Терапьютикс Лимитед (Au) Химерные антитела с областями приматов нового света
WO2008039553A1 (en) * 2006-02-10 2008-04-03 Zymogenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
KR102050040B1 (ko) * 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
WO2012017328A2 (en) * 2010-08-06 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases

Also Published As

Publication number Publication date
GB2498276A (en) 2013-07-10
UA112747C2 (uk) 2016-10-25
CA2807540A1 (en) 2012-02-09
GB2498276B (en) 2018-05-23
EP2601967A1 (en) 2013-06-12
WO2012018284A1 (ru) 2012-02-09
US20130224219A1 (en) 2013-08-29
EA030411B1 (ru) 2018-08-31
EA201300136A1 (ru) 2013-09-30
AU2011286486B9 (en) 2017-02-23
RU2535033C2 (ru) 2014-12-10
AU2011286486A2 (en) 2013-05-02
JP2013538195A (ja) 2013-10-10
ES2555557A2 (es) 2016-01-04
RU2010133045A (ru) 2012-02-20
DE112011102649T5 (de) 2013-06-20
GB201303983D0 (en) 2013-04-17
AU2011286486A1 (en) 2013-03-28
CN103209705A (zh) 2013-07-17
EP2601967A4 (en) 2014-05-07
ES2555557R1 (es) 2016-02-05
AU2011286486B2 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
NZ606992A (en) Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
EP3497133A4 (en) TREATMENT AND DELAYED VIROLOGICAL REMISSION OF HIV INFECTIONS BY ANTIBODIES AGAINST CD4 IN HAIR-STABILIZED PATIENTS
IN2014DN03054A (https=)
PH12013500233A1 (en) Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein
UA104484C2 (uk) Противірусна сполука множинної дії, її склад та спосіб лікування вірусних захворювань
EA201300134A1 (ru) Фармацевтическая композиция и способ лечения и профилактики заболеваний, вызванных или связанных с вич
UA49146U (ru) Лекарственный препарат для перорального применения
UA67522U (ru) Способ повышения чувствительности к цефатоксиму музейного штамма золотистого стафилококка атсс 25923
PH12014502497A1 (en) New treatments of hepatitis c virus infection
UA79040U (ru) Способ лечения ВИЧ-инфекции
UA59657U (ru) Способ лечения женщин с фоновыми заболеваниями шейки матки на фоне генитальной герпесвирусной инфекции
UA69690U (ru) Способ лечения больных с синдромом повышенной утомляемости на фоне хронической тонзиллярной инфекции
UA74047U (ru) Способ лечения хронического гепатита с на фоне вич-инфекции
UA90646C2 (ru) Способ лечения часто рецидивирующей хронической герпетической инфекции, вызванной вирусом герпеса простого и и ии типов
UA82641U (ru) Способ лечения нейросифилиса с паренхиматозными изменениями
UA53381U (ru) Способ получения средства с мембраностабилизирующим действием
UA59272U (ru) Способ лечения рецидивных форм аллергодерматозов у больных с наличием вторичных иммунодефицитов
UA96250U (uk) Спосіб лікування інфекційного мононуклеозу у дітей
UA56226U (ru) Способ лечения и профилактики послеоперационных рубцов у крыс, прооперированных по поводу нейрохирургической патологии, с использованием электрофореза препарата стекловидное тело
UA48606U (ru) Способ лечения больных негоспитальной пневмонией, соединенной со стеатозом печени
UA69264U (ru) Способ профилактики развития инфертильности у мужчин с малосимптомными формами хронической инфекции урогенитального тракта
UA58066U (ru) Способ лечения генитальной вирусной инфекции
UA74055U (ru) Способ хирургического лечения рефрактерных форм глаукомы
UA56353U (ru) Способ возобновления проходности слезоносового канала у детей с введением лекарственного средства

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JUL 2018 BY FPA PATENT ATTORNEYS PTY LTD

Effective date: 20161026

LAPS Patent lapsed